Bio-Techne’s Advanced Cell Diagnostics (ACD) sets new standard in spatial biology with protease-free RNAscope multiomics

Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, has set a new standard with the development of a next-generation, protease-free RNAscope spatial multiomics workflow.

Unveiling the truth: tropical hunter-gatherers’ diets contradict Paleo diet assumptions

Researchers assessed the dietary variations of tropical hunters and gatherers.

June 26, 2023

It’s time for the FDA to halt Cassava Sciences’ Alzheimer’s clinical trials

The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease. That, and other thoughts on the fallout from the City

October 17, 2023

Investigational gene therapy shows promise for rare childhood neurodegenerative disease

An investigational gene therapy for a rare neurodegenerative disease that begins in early childhood, known as giant axonal neuropathy (GAN), was well tolerated and showed

March 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.